Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,957
  • Shares Outstanding, K 44,664
  • Annual Sales, $ 20,600 K
  • Annual Income, $ -8,610 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.16
  • Price/Sales 1.93
  • Price/Cash Flow N/A
  • Price/Book 0.75
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings $0.25 on 03/04/26
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 230.53% (+4.59%)
  • Historical Volatility 73.03%
  • IV Percentile 8%
  • IV Rank 23.13%
  • IV High 861.62% on 07/15/25
  • IV Low 40.63% on 03/17/26
  • Expected Move (DTE 10) 0.0340 (3.71%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 150
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,213
  • Open Int (30-Day) 2,340
  • Expected Range 0.8830 to 0.9510

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 1
  • High Estimate $-0.10
  • Low Estimate $-0.10
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7620 +17.68%
on 03/31/26
0.9580 -6.40%
on 03/16/26
+0.0967 (+12.09%)
since 03/06/26
3-Month
0.6349 +41.23%
on 01/15/26
0.9580 -6.40%
on 03/16/26
+0.2556 (+39.87%)
since 01/07/26
52-Week
0.5650 +58.71%
on 11/17/25
1.3100 -31.55%
on 09/12/25
+0.0881 (+10.90%)
since 04/07/25

Most Recent Stories

More News
SCYNEXIS Announces $40.0 Million Private Placement

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies...

SCYX : 0.9059 (-1.21%)
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concept...

SCYX : 0.9059 (-1.21%)
Scynexis: Q4 Earnings Snapshot

Scynexis: Q4 Earnings Snapshot

SCYX : 0.9059 (-1.21%)
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a...

SCYX : 0.9059 (-1.21%)
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

SCYX : 0.9059 (-1.21%)
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

SCYX : 0.9059 (-1.21%)
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant,...

SCYX : 0.9059 (-1.21%)
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

SCYX : 0.9059 (-1.21%)
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to...

SCYX : 0.9059 (-1.21%)
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation...

SCYX : 0.9059 (-1.21%)

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 1.0210
2nd Resistance Point 0.9854
1st Resistance Point 0.9512
Last Price 0.9059
1st Support Level 0.8814
2nd Support Level 0.8458
3rd Support Level 0.8116

See More

52-Week High 1.3100
Fibonacci 61.8% 1.0254
Fibonacci 50% 0.9375
Last Price 0.9059
Fibonacci 38.2% 0.8496
52-Week Low 0.5650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.